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Abstract
We used deep sequencing technology to profile the transcriptome, gene copy number, and CpG island methylation status
simultaneously in eight commonly used breast cell lines to develop a model for how these genomic features are integrated
in estrogen receptor positive (ER+) and negative breast cancer. Total mRNA sequence, gene copy number, and genomic
CpG island methylation were carried out using the Illumina Genome Analyzer. Sequences were mapped to the human
genome to obtain digitized gene expression data, DNA copy number in reference to the non-tumor cell line (MCF10A), and
methylation status of 21,570 CpG islands to identify differentially expressed genes that were correlated with methylation or
copy number changes. These were evaluated in a dataset from 129 primary breast tumors. Gene expression in cell lines was
dominated by ER-associated genes. ER+ and ER2 cell lines formed two distinct, stable clusters, and 1,873 genes were
differentially expressed in the two groups. Part of chromosome 8 was deleted in all ER2 cells and part of chromosome 17
amplified in all ER+ cells. These loci encoded 30 genes that were overexpressed in ER+ cells; 9 of these genes were
overexpressed in ER+ tumors. We identified 149 differentially expressed genes that exhibited differential methylation of one
or more CpG islands within 5 kb of the 59 end of the gene and for which mRNA abundance was inversely correlated with
CpG island methylation status. In primary tumors we identified 84 genes that appear to be robust components of the
methylation signature that we identified in ER+ cell lines. Our analyses reveal a global pattern of differential CpG island
methylation that contributes to the transcriptome landscape of ER+ and ER2 breast cancer cells and tumors. The role of
gene amplification/deletion appears to more modest, although several potentially significant genes appear to be regulated
by copy number aberrations.
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Introduction
The advent of massively parallel DNA sequencers has opened
new vistas on cancer genomics. Wide dynamic range and high
signal to noise ratio facilitates sequence-based genomic profiling of
low abundance transcripts, which cannot be reliably detected
using microarrays. Deep sequence analysis of restriction endonu-
clease fragments from bisulfate-treated genomic DNA fragments
makes it possible to quantify changes in CpG island methylation
status, and low depth quantitative DNA sequence analysis
provides a rapid means to identify genes that are either amplified
or deleted during transformation.
However, our ability to generate detailed sequence information
has significantly outstripped the power of the available analytical
pipelines in many cases. A major objective of our studies has been
to produce and to make publicly available a comprehensive
sequence-based dataset that can be used to develop new analytical
pipelines. A more daunting challenge is the development of
quantitative models that describe the relationship between diverse
genomic features such as mRNA abundance, epigenetic modifi-
cation, and gene copy number. It is our belief that such a systems
biology approach will eventually enable the incorporation of
multiple genomic features into a quantitative model of the
genomic landscape of individual tumors, and that such a
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17490perspective will be clinically useful for stratification of tumors for
prognostic and/or predictive applications. We currently lack the
ability to generate such models, but we submit that the availability
of detailed sequence-based genomic datasets of the sort that we
present below provides a valuable resource for the development of
such analytical pipelines. To this end we have carried out deep
sequence analysis of eight well-characterized human breast cancer
cell lines. These data have been broadly analyzed with a view
towards assessing the extent to which copy number aberration
and/or differences in CpG island methylation account for
differential gene expression in cohorts of cells that model clinically
relevant states. Specifically, we have focused on comparison of a
panel of breast cancer cell lines that either express or do not
express estrogen receptor-a (the product of the ESR1 gene,
hereinafter called ER).
Several studies using cDNA/oligonucleotide microarray or
SAGE (serial analysis of gene expression) have shown that ER+
and ER2 breast cancers have very different gene expression
profiles that can be used for molecular diagnosis and outcome
prediction [1–4]. These findings suggest that a subset of genes co-
expressed with ER could play an important role in establishment
and maintenance of the transformed state and in determining the
hormone-responsive breast cancer phenotype [5]. However, the
underlying mechanisms that account for differential regulation
and function of these genes are largely unknown. In this study we
applied next generation cDNA sequencing technology (mRNA-
seq) to quantify mRNA abundance and identify genes that are
differentially expressed in a panel of well-characterized ER+ and
ER- cell lines at a depth of analysis that has not yet been achieved
by conventional microarray analyses. Low depth DNA sequence
analysis (DNA-seq) was used to quantify gene copy number to a
depth of about 1 sequence tag every 300 bp, with a view towards
determining if there are common patterns of gene amplification or
deletion that underlie aspects of the genomic profiles that are
associated with the ER+ or ER2 phenotypes. Finally, bisulfite-
treated DNA fragments (Methyl-seq) were sequenced to quantify
changes in CpG island methylation and to determine if there are
systematic patterns of methylation that may contribute to
differential gene expression in ER+ versus ER2 cells. These
analyses were carried out simultaneously for 7 commonly used
breast cancer cell lines (MCF7, T47D, BT474, ZR75-1, BT20,
MDA-MB-231, MDA-MB-468) and 1 non-tumor breast cell line
(MCF10A). This dataset represents one of the most comprehensive
genomic portraits of a collection of tumor cell lines reported to
date; and, from an analytical perspective the dataset has
considerable utility for developing analytical pipelines to mine
sequence-based genomic data as well as to evaluate the relative
contributions of promoter methylation and gene copy number
aberrations in defining patterns of gene expression. Our initial
analysis has identified a cohort of genes that are differentially
expressed in ER+ and ER2 cell lines, associated with changes in
gene copy number or CpG island methylation status in such cells,
and differentially expressed in ER+ and ER2 primary human
breast tumors. Several of these genes have been implicated in
hormone responsiveness and disease progression.
Results
mRNA expression patterns are associated with ER status
We carried out 50 nt paired end mRNA-seq analysis on 8 cell
lines. Seven cancer cell lines were used in this comparison: 4 ER+
and 3 ER2. The non-tumorigenic cell line MCF10A was excluded
in our initial comparison of mRNA abundance in tumor cell lines.
Initially, we identified and excluded 710 genes that had 0 mapped
readsinallsamples,whenmappedto the18,517annotatedgenesin
the RefSeq RNA database (release 30, 2008). The reads/million
(RPM)normalized, log2 transformed data for the remaining17,807
exhibited very similar distribution from sample to sample when
displayed as a box plot (Figure 1A). As expected, genes that were
expressed at low levels were more variable among cell lines, as
shown in the mean versus standard deviation plot (Figure 1B).
Unsupervised clustering using all genes (Figure 1C) demonstrated
that ER+ and ER2 cell lines formed two distinct clusters consistent
with published microarray data from tumor samples [1,4]. Similar
results were obtained when unsupervised clustering was carried out
with a subset of 4450 genes with standard deviation above 75
percentile (data not shown). Because of the small number of
samples, we were concerned that the hierarchical relationship
shown in Figure 1C might be random. To evaluate this possibility,
we carried out 100 iterations in which we perturbed by adding
artificial noise to the dataset as described by McShane and
colleagues [6]. The noise was estimated from the dataset by
calculating the variance of each gene among the cell lines and then
using the median of these variances to define the variance of the
noise, which were then randomly selected and added to the original
data for re-clustering 100 times. At the point of two clusters that
separated ER+ and ER2 cell lines, we obtained an R (Robustness)
index of 1 and a D (Discrepancy) index of 0, suggesting the strong
reliability of the clusters.
We applied two additional filters to eliminate variable genes that
were expressed at low abundance (Figure 1B). Initially, we filtered
the 17,807 genes to eliminate those with average raw counts less
than 50 (mean RPM,#1, corresponding to log2 mean expres-
sion=0 in Figure 1B) in both ER+ and ER2 groups. We also
required that every gene, in addition to having .50 average raw
counts in one group of samples, must also have at least 5 raw
counts in every sample in that same group. These filters reduced
the dataset to 12,487 genes, of which 1,873 were differentially
expressed in ER+ and ER2 cancer cell lines, as defined by
p,0.05 (FDR q,0.2) from moderated (LIMMA) t-statistics and
fold change greater than 1.5. A ‘volcano plot’ illustrating
differential expression (red symbols) as a function of fold change
and p-value is shown in Figure 1D. Figure 1E illustrates the
frequency distribution of p-values for this dataset, which manifests
a peak frequency in the range of 0#p#0.05. The reference line in
Figure 1E illustrates the p-value distribution that would be
expected if differential expression reflects random chance. The
identities of these 1,873 differentially expressed genes as well as the
LIMMA statistics that support their identification are provided in
Table S1. The heatmap shown in Figure 1F contains the top 100
differentially expressed genes (defined by p-value) and illustrates
the consistency with which this subset of genes were differentially
expressed in the ER+ and ER2 cell lines.
Validation of mRNA-seq data
Initially, we compared the abundance of the three sentinel
markers of our cell lines (ER/ESR1, PR/PGR, and HER2/
ERBB2) using qPCR data that we had originally generated to
confirm the receptor status of the cell lines. As shown in Figure 2A,
there was generally good correlation between the qPCR and
mRNA-seq data for these three transcripts. We then used the
NanoString nCounter and the Cancer Reference codeset to
extend our validation to 236 cancer-related genes. The RPM-
normalized mRNA-seq total counts for each of these genes are
shown in comparison to the nCounter counts in Figure 2B. Very
high correlations were observed between mRNA-seq and Nano-
String data for each of the 7 cancer cell lines (Pearson correlation
coefficients ranging from 0.84 to 0.9).
Gene Expression, Methylation, CNA in Breast Cancer
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differentially expressed (p,0.05) in the mRNA-seq data. The
expression data for these genes is plotted as log2 fold change (ER+
versus ER2) in Figure 2C, which shows a very high degree of
correlation (R=0.97) between the NanoString and mRNA-seq
dataset. The data indicate the quantitative precision of the
sequence-based approach for identification of differentially
expressed transcripts.
Differentially expressed genes are involved in ER-
associated pathways
We conducted a pathway analysis for 451 genes with q-value
less than 0.1 (corresponding to p-value less than 0.005) and log2
fold change.61.3. Twenty seven canonical pathways and 25
biological process networks were significantly enriched at p-value
less than 0.05, as listed in Table S2. We noted that several
significantly enriched pathways/networks are linked to ER
function or expression, consistent with the receptor status of the
cell lines.
Global methylation patterns correlate with ER status
The human genome contains 25,328 annotated CpG islands
with overlapping MspI restriction sites. For purposes of analysis, we
required at least 106coverage of each dCMP residue within every
CpG island, and the average of all dCMP residues within each
island was calculated as described in the Materials and Methods.
We analyzed 21,570 CpG islands that met these criteria in all
seven breast cancer cell lines, which represents 85% of the total
MspI-bounded CpG islands in the genome. We conducted
unsupervised clustering using the methylation data of all 21,570
CpG islands. As shown in Figure 3A, three ER+ cell lines BT474,
ZR751, and MCF7, were in the neighboring nodes of the cluster,
and two ER- cell lines BT20 and MDAMB231 clustered.
However, T47D (ER+) and MDAMB468 (ER-) did not cluster
with ER+ and ER2 samples, respectively. The data suggest that
global genomic methylation status varies in a systematic manner
between ER+ and ER2 cell lines; however, the association
between CpG island methylation and ER status is not as robust as
that observed for mRNA abundance (Figure 1C).
Among the 12,487 genes that were included in the mRNA
expression analysis, 9,968 had known CpG islands that mapped
within 5 kb of the genomic coordinates of the 59 end of the longest
known transcript. About 4% of these islands (444) were
differentially methylated (p,0.05) in ER+ versus ER2 cells.
The top 100 differentially methylated CpG islands, determined by
rank order p-value, were visualized in a heatmap (Figure 3B),
which illustrates a very robust methylation signature for these CpG
islands in the ER+ and ER2 cell lines. All significantly methylated
CpG islands and their associated mRNA expression data are
provided in Table S3.
Of the 444 CpG islands that were differentially methylated in
ER+ and ER2 cell lines, 164 islands were located within 5 kb of
the promoters of 162 differentially expressed genes. The
relationship between the mean methylation difference and the
log2 fold change for those 162 genes is shown in Figure 4A
(Pearson correlation coefficient=20.75 with 95% confidence
interval: 20.81 to 20.68 and regression p-value,2.2e-16). A
strong negative correlation was observed between methylation
status and expression for most of these genes, although there were
a number of outliers (13 genes) in which methylation status
appeared to be unrelated to expression. We observed a strong
inverse correlation between methylation status of 151 CpG islands
and expression of 149 associated genes.
These differentially expressed genes also exhibited an inverse
relationship between the magnitude of differential gene expression
(log2 fold change) and distance of a CpG island to the cognate
transcript start site (Figure 4B) indicating that proximity to the
promoter was a major factor in determining the extent to which
gene silencing was linked to promoter methylation. Analysis of the
distribution of CpG islands with respect to the 59 end of the
differentially expressed transcripts indicates that the median
distance from the differentially methylated CpG islands to the
transcriptional start site is around 300 bp (Figure 4C), consistent
with a role in affecting promoter activity. These 149 genes are
listed in Table 1, with detailed expression data in Table S4. The
strong inverse correlation between methylation status of these
promoter-proximal CpG islands and mRNA abundance of the
cognate transcripts is consistent with the conclusion that a subset
of those genes that define the ER+ and ER2 gene expression
profiles are likely to be regulated by tumor subtype specific
changes in the global pattern of CpG island methylation.
Differential gene amplification and deletion is related to
ER status
DNA-seq analysis was carried out as described in Materials and
Methods to a theoretical coverage of one tag distributed
approximately every 300 across the genome. Copy number
aberrations were identified by comparing the number of sequence
tags that aligned to the genome in each tumor cell line to non-
tumorigenic MCF10A cells. Every cell line exhibited 100–200
statistically significant copy number differences, compared to
MCF10A (Figure 5A). We identified 1,003 genomic regions that
exhibited statistically significant copy number changes (Table S5)
in one or more of the cancer cell lines. We focused our analysis on
799 copy number aberrations that were found in at least two of the
samples; 479 (out of 1,873) differentially expressed genes were
mapped to these regions, suggesting that differential expression, in
some cases, might result from gene copy number differences.
However, comparison of the log2 fold change of the mRNA
between ER+ vs. ER2 sample groups that corresponds to these
Figure 1. Total mRNA sequence analysis identifies a cohort of genes that are differentially expressed in ER+ and ER2 cell lines.
Panel A: A box plot of total read normalized (RPM) log2 transformed data for 7 breast cancer cell lines. Panel B: RPM mean versus standard
deviation (SD) of 7 cell lines showing variation is much higher in low abundance transcripts. Log2=0 corresponds to ,1 RPM or about 50 raw counts.
Panel C: An unsupervised clustering using all genes for 7 cell lines. The graded colors from red, orange, to yellow represent correlation from high to
low among samples. ER+ and ER2 cell lines are in two different clusters. Panel D: A volcano plot for differentially expressed genes identified using
LIMMA statistical model. The red circles indicate genes significant at p,0.05 and fold change .1.5. Panel E: p-value distribution of all genes in the
analysis indicates that p-values are not uniformly distributed, as would be predicted if the distribution of p-values were random. Random frequency
distribution was approximated by assuming that if the distribution were random, the p-values for individual genes would be uniformly (equally)
distributed across the different bins of p-values. From this assumption, we estimated the number of genes that would distribute to each bin by
dividing the total number of genes by 20 bins. This calculation estimates a random frequency of ,624 genes in each p-value bin simply by chance, as
indicated by the dashed line. Panel F: A heatmap showing the strict assortment of ER+ and ER2 tumors based on the top 100 differentially
expressed genes identified using the LIMMA model. Gene expression was standardized by the mean among the samples, red indicating higher
expression and green for lower expression.
doi:10.1371/journal.pone.0017490.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17490Figure 2. The mRNA-seq data validate in comparison to qPCR and NanoString data. Panel A: A comparison of the abundance of three
transcripts (ESR1, PGR, and ERBB2) measured by mRNA-seq (blue symbols) or qPCR (red symbols). Panel B: A correlation plot between mRNA-seq and
NanoStringfor236 cancerreferencegenes.Log2RPMdataformRNA-seqandlog2NanoStringdatawereused.Rwas usedtocalculatethePearsoncorrela-
tion coefficient. Panel C: log2 fold change correlation between mRNA-seq and NanoString for 25 differentially expressed genes detected by NanoString.
doi:10.1371/journal.pone.0017490.g002
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difference of the corresponding genomic coordinated in ER+ and
ER2 sample groups showed only moderate positive correlation
(correlation coefficient=0.28). This rather weak correlation prob-
ably reflects the fact that most copy number aberrations appear to
be cell specific and not strictly associated with the ER status.
We did identify regions on chromosome 8 and 17 that were
consistently amplified or deleted in either ER+ or ER2 cell lines.
These included a region from 125,504,248 to 126,521,417 on
chromosome 8 wherein all three ER2 cell lines exhibited
statistically significant copy number loss with no chromosome copy
number change in 4 ER+ cell lines. These data are summarized in
Figure 5B, which compares gene copy number in ER+ and ER2
cell lines (blue=deleted in ER2, gray=no change in ER+). Eight
genes mapped to this locus exhibited significantly higher expression
in ER+ cell lines (red=overexpressed in ER+).
AllER+ cell lines exhibited gene amplification inchromosome 17
from 44,246,133 to 63,413,540 with no change in copy number in
any of the ER2 cell lines (Figure 5C, red=amplified in ER+,
gray=no change in ER2). This locus contains 22 genes that were
moreabundantinER+celllines(Figure5C,red=overexpressionin
ER+ relative to ER2). A few genes within this locus appeared to be
overexpressed in ER2 (as indicated by blue bars), however none of
these achieved statistical significanceat thelevel of p,0.05. Overall,
some 30 genes appear to be consistently overexpressed as a result of
chromosome 8 deletion in ER2 cells or chromosome 17
amplification in ER+ cells. These genes are listed in Table 2, with
detailed expression and amplification data in Table S6.
The methylation/expression signature defined in cell
lines is significantly enriched in a cohort of breast cancer
samples
A recent genomic methylation analysis of 12 ER+ and 12 ER2
tumors [7] identified 5 loci that are consistently hypermethylated
in one or the other tumor type (MANEAL, PER1, NAV1,
FAM124B, and ST6GALNAC1). Among these only MANEAL,
NAV1, and PER1 had CpG islands within 5 kb of the 59 end of the
gene, and only the CpG island associated with the NAV1 promoter
was differentially methylated (p=0.019, difference in percent
methylation=52.3%) in our cell lines. NAV1 was also differentially
expressed (log2 fold change=4.1); however, the increased NAV1
mRNA was observed in cells in which this CpG island was
hypermethylated, so this gene is unlikely to be regulated by
methylation of this particular site.
The published global methylation data are consistent with our
results on global CpG island methylation in cell lines (Figure 3A);
the differences in global methylation patterns are not as robust as
the differential expression data, and it is generally difficult to
predict gene expression patterns in ER+/ER2 tumor samples
based on overall genomic methylation patterns. However, a much
more robust methylation/expression signature emerges when one
combines differential expression and differential CpG island
methylation data. Our analyses identified a cohort of 149
methylated genes that contribute to the genomic profiles of ER+
and ER2 breast cancer cell lines. We organized 148 of these
methylation signature genes into a geneset. [One methylation
signature gene, LRCC26, was not represented on the Affymetrix
and was not included in our analysis.] This geneset was then used
to carry out geneset enrichment analysis (GSEA) of an open source
dataset derived from Affymetrix microarray analysis of 76 ER+
and 53 ER2 primary breast tumors [8] (GEO accession number:
GSE5460). The 148 gene methylation geneset was significantly
enriched between ER+ and ER2 tumors, as evidenced by a
normalized enrichment score=1.95, p,0.001, with FDR
q=0.063. By way of comparison, a geneset of 30 known ER
target genes [9] exhibited a normalized enrichment score=2.01,
p=0.002, FDR q=0.037 in this dataset from ER+/ER2 tumors.
A heatmap representing the expression of the 148 methylation
signature genes plus 30 CNA candidate genes (identified as
Figure 3. ER+ and ER2 cell lines exhibit differential CpG island methylation. Panel A: Unsupervised clustering of cell line data using 21,570
CpG islands, filtered for CMP methylation coverage as described in Materials and Methods. The graded colors from red, orange, yellow, to white
represent correlation from high to low among samples. Panel B: A heatmap of the top 100 differentially methylated CpG islands identified using the
LIMMA model. The methylation data for each CpG island were standardized by mean among the samples where red represents hypermethylation
and green hypomethylation. Genes associated with these CpG islands are indicated on the right of the figure.
doi:10.1371/journal.pone.0017490.g003
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which our focus genes are differentially expressed in ER+/ER2
primary tumors (Figure 6). We identified 67 genes that were i)
overexpressed in ER+ cell lines, ii) hypermethylated in ER2 cell
lines, and iii) overexpressed in primary ER+ tumors. In addition,
17 genes were i) overexpressed in ER2 cell lines, ii) hyper-
methylated in ER+ cell lines, and iii) overexpressed in ER2
primary tumors (Table 1). We conclude that combining CpG
island methylation and expression data is a powerful way to
identify a robust methylation/expression signature that defines at
least part of the transcriptome landscape of ER+ and ER2
breast cancer cells and tumors. Many of these genes are
potentially important for establishment and/or maintenance of
the tumor phenotype.
Figure 4. There is an inverse correlation between methylation status of promoter-proximal CpG islands and mRNA abundance.
Panel A: A scatter plot and trend line between fold change of gene expression and mean difference of methylation between ER+ and ER2 cell lines.
The Pearson correlation coefficient R is 20.75 [95%CI: 20.81, 20.68] with p-value,2.2e-16. Panel B: The distance from the start of each of the CpG
islands that exhibited inverse correlation with mRNA abundance, illustrated in Figure A, to the start of the corresponding gene plotted against log2
gene expression fold change between ER+ and ER2 cell lines. Panel C: A histogram representing the distribution of differentially methylated CpG
islands in 149 differentially expressed genes.
doi:10.1371/journal.pone.0017490.g004
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are hypermethylated in ER2 cells and overexpressed in ER+ cells
and tumors. Among this cohort, the greatest difference in
methylation status was exhibited by C6orf97 (Figure 7A). All three
ER2 cell lines exhibited almost complete methylation (mean
difference %CpG methylation ER+ minus mean difference
%CpG methylation ER2=286%) of a single CpG island located
adjacent to the C6orf97 promoter (p=6.1E-05); and C6orf97
mRNA was very significantly overexpressed in ER+ tumors
(p=2.9E-12). The function of C6orf97 is unknown. However, two
recent large scale genome-wide association studies identified single
nuclear polymorphisms (SNPs) in or near this locus which are
associated with increased breast cancer risk [10,11]. SYNE1,
located near C6orf97 on chromosome 6, also exhibited hyper-
methylation in ER2 cell lines, but this gene was not differentially
expressed in the tumors analyzed in this study. C6orf97 also resides
adjacent to ESR1, which did not exhibit a statistically significant
difference in methylation status in our cell lines (Figure 7A).
High level expression of GATA3 in ER+ tumors has been
reported in a series of tissue-based studies [1,3,12]; and GATA3
overexpression is associated with favorable clinical outcomes,
including response to endocrine therapy [13,14]. GATA3 mRNA
is significantly overexpressed in ER+ tumors (p=2.10E-30). As
shown in figure 7B, there is a cluster of CpG islands within the
GATA3 gene that was highly methylated in ER2 cells, with little or
no evidence of methylation in ER+ cells (p=2.54E-06). An
uncharacterized locus (FLJ45984) resides immediately upstream of
GATA3 (Figure 7B), and this gene also showed evidence of
differential methylation and differential expression in cell lines.
Some of the CpG islands in this vicinity appear to overlap the
Table 1. 149 genes differentially expressed and inversely correlated with CpG island methylation.
Genes overexpressed in ER+ cell lines and hypermethylated in ER2 cell lines (117)
Genes overexpressed in ER2
tumors and hypermethylated in
ER+ cell lines (32)
ACOT4 CUX2 MPPED2 SEPT5 ACN9
ADAMTS13 CXCL12 MPV17L SIDT2 ADORA2B
ADAMTS19 CXXC5 MSI1 SLC16A6 AKR1B1
ADCY1 DNAJA4 MYRIP SLC16A9 ALDH1A3
AMPH DSCAML1 NAAA SLC1A2 ANKH
AMZ2 ENTPD2 NKD2 SLC29A4 CAV2
AR FGFR4 NOVA1 SLITRK4 CHST11
ASCL2 FKBP4 NPEPL1 SPATA2L CPNE8
ASTN2 FSCN2 NPNT SPATA7 EGFR
ATP2A3 GATA3 NPTXR SPNS1 EPHB2
ATP8B2 GFRA1 P2RX2 SRMS FMNL2
BTG2 GHR PALM ST6GALNAC2 FOSL1
C16orf14 GJD3 PATZ1 STK32B GPX1
C17orf28 GPR160 PAX9 STOM HS3ST1
C20orf134 GRIK3 PCP4L1 SYCP2 IGF2BP2
C3orf57 HS6ST3 PDZRN3 TMEM47 IGF2BP3
C6orf154 ID2 PGR TRPV4 KIFC3
C6orf97 IFT140 PLCB1 VPS37D LYN
CA8 IGFBP2 PRKCZ ZNF396 MALL
CACNA1H IGSF9B PRKG1 ZNF512B MSN
CACNA2D2 IL17RB PRUNE2 ZNF703 NEXN
CADM1 JAM2 PSTPIP2 NPAS2
CAMK2B KCNH1 PTGER3 PLAC8
CASKIN1 KCNK6 RAPGEFL1 PPARG
CELSR1 KCNMA1 RHBG RIN3
CGREF1 KIF12 RHOT2 SEMA7A
CHDH KIFC2 RICH2 SLC19A3
CHST1 KLHDC9 RND2 TEC
CLUAP1 LMX1B RNF40 TXNRD1
CNTNAP2 LRRC26 SAMD11 UPP1
CPLX1 MAPK8IP2 SDC2 VLDLR
CRIP2 MMP17 SEMA6A ZNF502
Genes in bold face were also differentially expressed between 76 ER+ and 53 ER2 breast tumors and were consistent with cell line expression and methylation data.
Among these, 67 were overexpressed in ER+ tumors and 17 were overexpressed in ER2 tumors. Detailed gene expression and methylation data for the 149 genes (153
CpG islands) in the cell lines can be found in Table S4.
doi:10.1371/journal.pone.0017490.t001
Gene Expression, Methylation, CNA in Breast Cancer
PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e17490Figure 5. Gene copy number aberrations are associated with differential gene expression. Panel A: A histogram of the number of
statistically significant CNAs identified in each cell line. Panel B: IGV (Integrative Genomics Viewer) view of copy number aberrations for the region of
chromosome 8 that is deleted in all three ER2 cell lines. Panel C: Genomic view of copy number aberrations for the regions of chromosome 17 with
amplification in all four ER+ cell lines. The symbols and abbreviations in Panels B and C are as follows: CNA - the copy number aberration track for
each individual cell line; red represents amplification, blue deletion, and gray no change. Gene expression – the differential gene expression track; red
represents overexpression in ER+ cells, blue represents overexpression in ER2 cells, shown as log2 fold change.
doi:10.1371/journal.pone.0017490.g005
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promoter.
We identified 17 genes that exhibited hypermethylation in ER+
cell lines and were overexpressed in ER2 cell lines and tumors.
CpG island methylation status of two such genes (LYN and CPNE8)
is shown in Figure 7. LYN (Figure 7C) exhibited preferential
methylation of a promoter-proximal GpG island in ER+ cell lines
(p=0.036), and LYN mRNA was consistently overexpressed in
ER- tumors (p=1.05E-09). High level expression of LYN,a
member of the SRC family of non-receptor tyrosine kinases, has
been associated with epithelial/mesenchymal transition and
invasion by breast cancer cells and with poor survival of breast
cancer patients [15]. Our data suggest that suppression of LYN
expression in ER+ tumors may be linked to an epigenetic program
that limits metastasis and favors better clinical outcome.
Figure 7D shows differential methylation of CPNE8 (p=0.007)
in ER2 cells. Among the genes that exhibited differential
methylation, CPNE8 exhibited the greatest difference in hyper-
methylation status in ER+ cell lines. A single promoter-proximal
CpG island was highly methylated in the ER+ cell lines, with no
evidence of methylation in the ER2 cells (mean difference 77%).
CPNE8 is a member of the copine family of calcium-dependent
phospholipid-binding proteins. The function of CPNE8 is un-
known, although other copine family members have been
implicated in HER2 signaling and invasion in breast cancer
[16]. CPNE8 was differentially expressed in ER2 tumors
(p=4.95E-04); and, given that our data suggest that CPNE8 is a
very strong component of the methylation signature of ER2 cells,
the function of this gene warrants additional consideration.
Combination of copy number aberration and expression
data defines a CNA/expression signature that is partially
reflected in ER+ and ER2 tumors
A recent array comparative genomic hybridization study of 103
breast tumors identified a number of loci that exhibit copy number
aberration at a significant frequency in tumor samples [17], and a
Table 2. 30 differentially expressed genes in the consistent CAN.
Gene expression Copy number (log2 ratio relative to MCF10A)
Chr Genes log2 FC* p value BT474 MCF7 T47D ZR751 BT20 MDAMB231 MDAMB468
8 TRMT12 1.732 0.012 0 0 0 0 21.216 22.166 21.326
8 RNF139** 1.997 0.003 0 0 0 0 21.216 22.166 21.326
8 TATDN1 1.620 0.031 0 0 0 0 21.216 22.166 21.326
8 NDUFB9 1.608 0.004 0 0 0 0 21.216 22.166 21.326
8 MTSS1 3.582 0.009 0 0 0 0 21.216 22.166 21.326
8 KIAA0196 1.317 0.010 0 0 0 0 21.216 22.166 21.326
8 NSMCE2 1.368 0.027 0 0 0 0 21.216 22.166 21.326
17 ATP5G1 1.187 0.046 2.032 1.062 0.650 0.697 0 0 0
17 UBE2Z 1.425 0.044 2.032 1.062 0.650 0.697 0 0 0
17 B4GALNT2 4.600 0.010 2.032 1.062 0.650 0.697 0 0 0
17 PHOSPHO1 3.221 0.003 2.032 1.062 0.650 0.697 0 0 0
17 NXPH3 3.520 0.004 2.032 1.062 0.650 0.697 0 0 0
17 SPOP 1.357 0.049 2.032 1.062 0.650 0.697 0 0 0
17 SLC35B1 1.162 0.019 2.032 1.062 0.650 0.697 0 0 0
17 TOM1L1 1.902 0.026 2.616 0.912 0.650 0.697 0 0 0
17 HLF 3.270 0.021 2.616 0.912 0.650 0.697 0 0 0
17 MKS1 1.884 0.004 1.204 1.551 0.650 0.937 0 0 0
17 SUPT4H1 1.285 0.025 1.204 1.551 0.650 0.937 0 0 0
17 MTMR4 1.037 0.040 1.204 1.551 0.650 0.702 0 0 0
17 RAD51C 1.668 0.017 2.287 3.534 0.650 0.702 0 0 0
17 TRIM37 2.080 0.048 2.287 3.534 0.650 0.702 0 0 0
17 C17orf71 2.607 0.020 2.717 1.984 0.650 0.702 0 0 0
17 DHX40 1.586 0.021 2.717 1.984 0.650 0.702 0 0 0
17 CLTC 1.458 0.025 2.717 1.984 0.650 0.702 0 0 0
17 TUBD1 1.945 0.033 2.717 3.914 0.650 0.702 0 0 0
17 RPS6KB1 2.202 0.037 2.717 3.914 0.650 0.702 0 0 0
17 APPBP2 2.577 0.019 2.372 3.914 0.650 0.702 0 0 0
17 GNA13 1.110 0.041 1.633 1.489 0.650 0.702 0 0 0
17 PITPNC1 1.569 0.020 0.698 1.489 0.650 0.702 0 0 0
17 BPTF 1.439 0.014 0.698 1.489 0.650 0.702 0 0 0
*mRNA-seq log2 fold change between 4 ER+ and 3 ER2 cell lines.
**Genes in bold face are significantly up-regulated (p#0.05) in ER+ tumors in the set of 129 breast tumor samples.
doi:10.1371/journal.pone.0017490.t002
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Overall, 112 genes exhibited copy number aberration in 50 or
more tumors. We carried out a meta-analysis to determine if the
products of these 112 genes were differentially enriched in ER+ or
ER2 tumor samples. GSEA analysis, using the tumor dataset
described above, revealed no significant enrichment (normalized
enrichment score=20.81, NOM p-value=0.625, FDR q-val-
ue=0.77). Overall, the array comparative genomic hybridization
data and our sequence-based analysis of copy number aberration
suggest that CNA varies widely from tumor to tumor and from cell
line to cell line such that only a small subset of genes that
consistently define the ER+ and ER2 states are likely to be
regulated by amplification or deletion.
In contrast, we were able to combine our CNA and expression
data to identify 30 genes that were overexpressed in ER+ cell lines
as a result of chromosome 17 amplification in ER+ cells or
chromosome 8 deletion in ER2 cells. Nine of these genes were
overexpressed in ER+ tumors (at p#0.05), as one would anticipate
if these genes were deleted in ER2 tumors or amplified in ER+
tumors. Two of these genes are on chromosome 8q24.13 (RNF139
at 125,487,008 and KIAA0196 at 126,036,502 ). RNF4 , a nuclear
receptor coregulator with ubiquitin ligase activity [18] [19], is
known to be translocated in renal tumors [20] and has been
implicated in ovarian cancer [21]. NXPH3, SPOP, TOM1L1, HLF,
CLTC, APPBP2, and BPTF are located within 20 Mbp of each
other on chromosome 17 between 46,970,127 and 65,821,640
(start to pter). NXPH3 and SPOP are adjacent to each other on
chromosome 17q21.33, and the observation that both are
overexpressed in ER+ tumors suggests that these two genes may
be co-amplified in most ER+ tumors, as is the case in ER+ cell
lines. NXPH3 encodes neurexophilin-3, which is overexpressed in
ER+ tumors (p=0.0006). Neurexophilin-3, a postulated alpha-
neurexin ligand, has never been implicated in cancer, to our
knowledge. However, other neurexophilin family members have
been implicated in neuroblastoma [22], prostate [23], ovarian
[24], and breast [24] [25] cancer. SPOP, located within 0.5 Mbp
of NXPH3 on 17q21.33, encodes speckle-type POZ protein. Like
NXPH3, SPOP is also significantly overexpressed in ER+ tumors
(p=4.84E-06). SPOP has been linked to CUL3-mediated attenu-
ation of signaling downstream of DAXX (death-associated protein
6) and hedgehog [26,27]. The observation that SPOP and the
adjacent NXPH3 genes are both amplified in ER+ cell lines and
overexpressed in ER+ tumors is consistent with the hypotheses
that these two genes may comprise an amplicon that is commonly
amplified in ER+ tumors. The fact that both SPOP and NXPH3
regulate degradation of transcription factors that are involved in
ER, NOTCH, and DAXX signaling further emphasizes the
potential significance of this hypothetical amplicon.
Discussion
Breast cancer therapy, perhaps to a greater extent than any
other field of oncology, is motivated by the concept that genotype
predicts therapeutic response. This is not a new concept, but
rather has its origins in the observation that expression of the
product of the ESR1 gene (ERa) predicts response to endocrine
therapy. More recent developments have linked overexpression of
ERBB2 (HER2) to clinical outcome and therapeutic response. The
advent of oligonucleotide-based microarray platforms has facili-
tated the development of several clinically useful gene expression
signatures, which offer the promise of incorporating genomic
features other than ER, PR, and HER2 into clinical management
of breast cancer patients. One such signature, widely used among
researchers but not yet risen to standard of clinical care, has
facilitated the stratification of breast tumors into four or five
intrinsic subtypes [2]; and there is good evidence to suggest that
each of these subtypes exhibits a predictable clinical phenotype
[28,29]. Such findings substantiate the belief, almost an article of
faith amongst genomic researchers, that one should be able to
develop predictive models that are based upon integration of
multiple genomic features. This concept defines the intersection
between clinical practice and systems biology.
To date, the integration of multiple genomic features into a
cogent mathematical model that predicts cellular phenotype has
been frustrated by the fact that the output from analytical
platforms that have been used is primarily analog. Consequently, it
is often difficult to compare microarray data from different
laboratories, or for that matter to compare data from the same
laboratory run at different times. How much more difficult, then,
to integrate data from hybridization-based analyses of gene copy
number, promoter methylation, and mRNA abundance? The
advent of massively parallel DNA sequencers holds the promise of
overcoming some of these difficulties. The output from sequencers
is digital, the signal to noise ratio is high, and dynamic range is
great. The computational simplicity of merely counting the
number of times a defined sequence tag appears within a
particular sample should, in theory, make it possible to develop
mathematical models that integrate any number of genomic
features, with the expectation that such models will at the very
least engender hypothetical predictions about the relationship
between the various features that comprise the model.
To build such models, one must first develop a curated,
disciplined dataset. The development of such a dataset was our
primary objective in the experiments described in this report. We
elected to focus on breast cancer because of the historical
significance of gene expression and therapeutic response in this
disease, as discussed above. We elected to use cell lines, rather than
primary tumors, because these cells are readily available to any
investigator who wishes to confirm or extend our genomic
findings. (Note that all of the experiments described above were
done with early passage cells that were purchased from ATCC.)
Furthermore, the cell lines that we selected have been studied
extensively by many investigators, so there is a strong cellular and
molecular background to draw upon for future studies. Critically
important to our objectives, we elected to use a single platform for
all of our genomic analyses, the Illumina Genome Analyzer, in the
belief that a disciplined analytical approach would facilitate our
ultimate objective of data integration. Finally, we elected to extract
both RNA and DNA from the same cell cultures to minimize
potential biological variation that might arise from subtle
differences in culture conditions. DNA extracted from these cells
was used for DNA-seq and Methyl-seq analysis, whereas
polyadenylylated RNA was used for mRNA-seq analysis. Addi-
tional features of the mRNA-seq analysis included the generation
of long read libraries (longer cDNA than the conventional mRNA-
seq protocol) and paired end sequence analysis. Exploitation of the
paired end data to quantify splice junctions and to identify novel
splicing isoforms and fusion gene products is ongoing at this time.
Figure 6. Expression of focus genes from cellular analyses in primary human breast cancer. The heatmap was generated from GSEA
analysis in which microarray data from 76 ER+ and 53 ER2 tumors were interrogated with a geneset consisting of 149 genes that were differentially
expressed and inversely methylated plus 30 genes that were overexpressed in ER+ cells and amplified in ER+ cells or deleted in ER2 cells.
doi:10.1371/journal.pone.0017490.g006
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features: mRNA abundance, gene copy number, and CpG island
methylation status. The decision to analyze these features as a
function of estrogen receptor status was obvious, given the clinical
significance of ER as a therapeutic marker. This focus was
substantiated by the very robust stratification of the cell lines based
on unsupervised clustering of the gene expression data. Several
points about the mRNA expression data warrant discussion.
Although not a major focus of this report, we compared several
different statistical models including ANOVA, negative binomial
regression, Poisson regression, and a Bayesian implementation of
the modulated t-test that had originally been developed for
microarray analysis (LIMMA). As a primary end point, we
compared each of these models for the ability to identify genes that
were differentially expressed, with the NanoString data considered
to be the ‘true’ test of differential expression. A separate
manuscript describing this comparison is in preparation, but our
analyses indicated that for this dataset, LIMMA was significantly
more reliable than any other model. Consequently, we used
LIMMA to assess the statistical significance of observed differences
in mRNA abundance and CpG island methylation.
The broad dynamic range of mRNA-seq analysis makes it
possible to detect transcripts that are present at very low
abundance, easily below the range of 1 tag/M. However, our
analysis of variance (standard deviation) as a function of expression
(total tags) indicates that this level of detection is probably not
within the range of reliable quantification. Therefore, we felt it was
necessary to exclude from our analysis a subset of 5,320 genes that
had average expression levels of ,50 total tags (,1 tag/M) in both
the ER+ and ER2 groups. We also eliminated genes that had
.50 total tags on average, but for which there were ,5 total tags
in one or more samples within either group. Among these, 580
genes were statistically significant, as assessed by p-value,0.05.
Thus we eliminated from our analyses a group of very low
abundance genes in which about 10% appeared to be differentially
expressed but were of such low abundance that we were not
confident of the quantification and meaningful integration with
methylation and CNA data. This point warrants additional
emphasis: mRNA-seq is capable of detecting transcripts at very
low levels, but quantification of such transcripts is problematic and
may require more detailed analysis of features such as exon
coverage.
We detected 1873 genes that were differentially expressed in
ER+ and ER2 cell lines, at a modest level of statistical stringency
(p,0.05, FDR q,0.2, fold change .1.5). Validation experiments
indicate that the mRNA-seq data generally conform to data
obtained with two different analytical platforms (qPCR and
NanoString). Pathway analysis of these genes revealed statistically
significant enrichment of known ER-associated functions. The
question then arises of the extent to which these differences in gene
expression profile can be linked to copy number aberrations or to
differential methylation of CpG islands located in the vicinity of
the cognate promoters.
We used segmentation analysis to compare copy number in the
tumor cells to that in non-transformed MCF10A cells. The use of
MCF10A as a reference standard is debatable, since these are not
normal human mammary epithelial cells. However, visual
examination of the distribution of CNV-seq sequence counts
across all chromosomes in this cell line revealed no notable regions
of gene amplification. The calculated chromosomal coverage in
our analyses was on average about one tag every 300 bp,
corresponding to 1006 physical coverage for a gene of 30 kb.
As one would expect, we detected many regions that exhibited
copy number aberration in each of the tumor cell lines. Most of
these were cell line-specific. However, we did identify 479 genes
that are differentially expressed in ER+ versus ER2 cells and that
may be regulated by changes in gene copy number in two or more
cell lines of either phenotype. However, we have focused our
analysis upon a core of 30 genes that are overexpressed either as a
result of amplification of chromosome 17 (in ER+) or deletion of
chromosome 8 (in ER2). These features were common to all ER+
or ER2 cell lines, suggesting that some of the genes within these
loci may be essential to establishment or maintenance of the ER+/
ER2 phenotypes.
The methylation signatures that we detected in these cells were
significantly more robust than the copy number aberrations. We
identified some 162 differentially expressed genes that exhibited
very highly significant changes in CpG island methylation and for
which methylation status correlated inversely with expression. Not
surprisingly, the majority of these CpG islands were very close to
the 59 ends of the differentially expressed genes. Our data suggest
that a minimum of 10% of the genes that define the ER+/ER2
expression profiles are likely to be regulated by promoter
methylation. This is almost certainly an underestimate, since our
analysis is likely to identify only those genes that exhibit very large
changes in methylation status.
Our analyses have identified a subset of 30 genes that are
overexpressed in ER+ cells and are either amplified in ER+ or
deleted in ER2 cells. In addition, we have identified 149 genes
that are differentially expressed in ER+ versus ER2 cells,
differentially methylated on one or more promoter-proximal
CpG islands, and exhibit an inverse correlation between CpG
island methylation and mRNA abundance. The observation that
common mechanisms underlie differential expression implies that
some or all of these genes are regulated by global genomic
processes that are central to establishment and/or maintenance of
the ER+/ER2 phenotypes. That hypothesis predicts that this
cohort of genes should be enriched in ER+/ER2 tumors, and our
GSEA analysis of a large microarray dataset from such tumors is
consistent with this prediction (p,0.001, q=0.06). Some 103 of
our 179 focus genes were differentially expressed in the tumor
dataset. Fourteen of the 30 genes that exhibited CNA in the cell
lines were differentially expressed in the tumors; however, only 9/
14 were overexpressed in ER+ tumors. Conversely, 84/149 of the
differentially methylated genes were coordinately and significantly
expressed in both ER+/ER2 cell lines and tumors. Included
among these were several genes that have been linked to clinical
outcome, notably GATA3 (hypermethylated in ER-cell lines and
repressed in ER2 cell lines and tumors) and LYN (hypermethy-
lated in ER+ cell lines and repressed in ER+ cell lines and tumors).
Our data are correlative in nature, and do not rigorously
establish a link between methylation status or copy number
aberration in cell lines and expression in tumors. Nevertheless, our
data are consistent with the hypothesis that there is a significant
Figure 7. Representative examples of methylation status and mRNA abundance for genes that are differentially methylated in cell
lines and differentially expressed in both cell lines and tumors. Panel A: C6orf97 (with SYNE1 and ESR1); Panel B: GATA3; Panel C: LYN; and
Panel D: CPNE8. On each figure, gene expression track represents the log2 fold change of gene expression between ER+ and ER2 cell lines, red for
up-regulation and blue for down-regulation in ER+ cell lines. Below that track is the methylation data for each cell line, which shows the average
percent of methylated CpGs (dynamic range 0–100%) in the CpG Islands that were interrogated in this analysis.
doi:10.1371/journal.pone.0017490.g007
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regulated by such mechanisms and to play important roles in
establishment and/or maintenance of the ER+/ER2 phenotypes
in breast cancer. Copy number aberration may be involved, but
our data suggest that only a few genes are likely candidates for ER-
specific amplification or deletion. Conversely, CpG island
methylation appears to be linked to differential expression of a
large cohort of genes that define the ER+ versus ER2 tumor
phenotype. Some of these genes are known to be functionally
significant (e.g. GATA3 and LYN) whereas the functional signifi-
cance of other genes can only be inferred (C6orf97) or is completely
unknown (COPN8). Overall, however, there is a very strong
indication that global methylation patterns are critical to breast
tumor phenotypes, including therapeutic response and clinical
outcome. Of particular interest are those genes that are
hypermethylated in ER+ cells and overexpressed in ER2 cells
and tumors, since these may include potential therapeutic targets
(e.g. LYN) that could be exploited to treat ER2 (basal/triple
negative) tumors.
Materials and Methods
Data sharing
All of the sequence data that were analyzed in this report have
been deposited in Gene Expression Omnibus (GSE27003).
Breast cell lines
Eight breast cell lines, 7 from breast cancer and one from non-
tumor breast epithelial cells, were obtained from the American
Type Culture Collection (ATCC). The characteristics of these cell
lines were confirmed by qPCR analysis of ER, PR, and HER2
mRNA. Among the 7 cancer cell lines, 4 are ER+ and 3 are ER2.
All cell lines were grown under conditions recommended by
ATCC and RNA and DNA were extracted from mid log phase
populations of low passage number cultures.
RNA preparation and sequencing
Total RNA extraction was performed using Exiqon’s miR-
CURY RNA Isolation Kit. Long-read mRNA-seq cDNA libraries
were prepared from 1mg of total RNA using a modification of the
Illumina mRNA-seq protocol. Briefly, mRNA was resolved using
poly-dT oligonucleotides attached to magnetic beads, fragmented
using divalent cations under elevated temperatures, and converted
to cDNA using random primers. After conversion of the cleaved
fragments into cDNA, the cDNA underwent blunt end repair,
addition of an ‘A’ base to the 39 blunt ends, and ligation of adapter
molecules which will be used for PCR amplification, bridge
amplification, and sequencing. The cDNA library was resolved by
gel electrophoresis using conventional Illumina protocols except
that we cut from the gel those cDNA fragments in the range of
300–400 bp. The increased fragment length is necessary to
accommodate paired end sequence analysis. The gel purified
cDNA fragments were amplified by PCR and sequenced using the
Illumina Cluster Station and Genome Analyzer. Paired-end
sequence analysis (51 cycles/end) was carried out using sequencing
primers that correspond to either end of the bridge-amplified
cDNA fragments so as to obtain 50 nt of sequence from either end
of every cDNA fragment.
mRNA-seq data analysis
The Illumina standard pipeline version 1.4 was employed for
processing of raw images to make base calls and generate sequence
reads. Reads were aligned to genome and exon junctions using
Illumina’s alignment tool Eland_RNA (NCBI36/UCSC hg18). A
maximum of two mismatches were allowed for first 32 bases in
each alignment, and reads that had more than two mismatches or
were mapped to multiple genomic locations (alignment score less
than 4) were discarded. The aligned sequence tags were
summarized and annotated using Illumina’s CASAVA tool
(version 1.0) and imported into the Genome Studio software.
The read counts for genes, exons, and exon junctions were
exported from Genome Studio. A total of 18,517 genes were
annotated using RefSeq RNA database and the raw read counts
were used for downstream analyses.
The same mRNA library preparation was sequenced from both
ends of each cDNA fragment twice (Paired-End sequencing) and
the raw read counts from each end were combined for increased
coverage. The combined reads for each gene were normalized by
the total reads of each individual cell line and then standardized to
reads per million (RPM, gene counts/total counts of each cell line
61 million). For differential gene expression analysis between ER+
and ER2 cell lines, we first eliminated genes without any reads
across all 7 cell lines. We added 1 to all the genes and samples
before converting to RPM so that we could deal with genes with
zero count in some of samples to facilitate log2 transformation.
The log2 transformed data were visualized by hierarchical
clustering and heat maps for all the genes first and then for a
subset of highly varied genes across seven cell lines (standard
deviation greater than 75
th percentile). The distance matrix was 1-
correlation and linkage method was average. Differentially
expressed genes between ER+ and ER2 cell lines were identified
using the linear models for microarray (LIMMA) package in R
[30]. This package uses an empirical Bayesian implementation to
estimate a standard error and has improved performance when an
experiment has a limited number of samples. False discovery rate
(FDR) was estimated using q-value [31]. As one of our goals was to
explore the underlying causes of differentially expressed genes
between ER+ and ER2 cell lines from methylation and DNA
abnormality perspectives, a generous nominal p-value cut-off of
0.05 was used for significant changed genes to correlate the gene
expression with the methylation and DNA copy number changes.
For pathway analysis of differentially expressed genes, we applied
a more stringent criterion of including only genes with a FDR of q-
value less than 0.1. We carried out concordance analysis in which
we compared the mRNA-seq data to expression data from the
same samples obtained using the NanoString cancer reference
gene set data (see below). In this analysis we compared LIMMA,
over-dispersed Poisson model, DESeq (negative binomial model),
and Student’s t-test for identification of differentially expressed
genes between ER+ and ER2 cell lines. We observed that
LIMMA processing of mRNA-seq data gave the highest
concordance with NanoString data. Therefore we selected
LIMMA for analyzing both mRNA-seq and Methyl-seq data.
Validation of mRNA-seq with qPCR and NanoString on a
set of cancer reference genes
The NanoString nCounter Cancer Reference CodeSet was
used to validate mRNA-seq data (http://www.nanostring.com/
products/assays/). This codeset contains a 39 biotinylated capture
probe and a 59reporter probe tagged with a fluorescent barcode,
two sequence-specific probes for each of 236 transcripts. Probes
were hybridized to 100 ng of total RNA for 19 h at 65uC, after
which excess capture and reporter probes were removed and
transcript-specific ternary complexes were immobilized on a
streptavidin-coated cartridge. All solution manipulations were
carried out using the NanoString preparation station robotic fluids
handling platform. Data collection was carried out with the
nCounter Digital Analyzer to count individual fluorescent
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sample. Normalization was carried out based on a standard curve
constructed using spike in exogenous control samples. Background
hybridization signal was determined using spike in negative
controls, and all mRNAs had fewer than mean background+2
standard deviations were considered to be below the limits of
detection.
The raw code count data from the nCounter Analysis System
were first normalized and background corrected. Specifically, a
normalization factor was calculated based on the relative number
of positive control counts in each sample. Genes with counts less
than the average of embedded negative controls (background
noise) in that sample were first set to its background. The gene
count for each gene was subtracted from this background so that
each sample had same footing where zero numbers represent
undetectable noise. When comparing the data to mRNA-seq data
and detecting differentially expressed genes, we log2 transformed
the data after each data point was increased by adding 1 to deal
with zeros. Correlation coefficients between the mRNA-seq and
NanoString data were determined using Pearson product-moment
correlation coefficient. Student’s t-test was applied to the Nano-
String data to identify differentially expressed genes between the
ER+ and ER2 cell lines.
CpG Island methylation by Reduced Representation
Bisulfite Deep Sequencing
DNA (2mg) extracted from cell lines was fragmented using
endonuclease MspI, followed by QIAQuick purification. The end
of digested DNA was repaired and an adenine was added to the 39
end of the DNA fragments according to the Illumina standard end
repair and add_A protocol (Illumina, San Diego, CA). Pre-
annealed forked Illumina adaptors containing 59-methyl-cytosine
instead of cytosine was ligated to both ends of DNA fragments
using standard Illumina adaptor ligation protocol (Illumina).
Ligated fragments were then separated by 2% agarose gel. Two
size ranges, 150–175 bp and 175–225 bp (includes adaptor
length), were selected and cut from the gel. DNA from gel slices
was purified using Qiagen Gel extraction kit (Qiagen). The
purified DNA was treated with EpiTect Bisulfite kit (Qiagen) with
modification. The bisulfite conversion time was extended to
approximately 14 hr by adding 3 cycles of denaturation at 95uC
for 5 min followed by incubation at 60uC for 180 min. The
bisulfite-converted DNA was purified using the EpiTect Bisulfite
kit and the protocol for DNA isolated from formaldehyde-fixed,
paraffin-embedded tissue samples. The bisulfite-treated DNA was
purified a second time with MinElute PCR purification kit
(Qiagen) and eluted with 15ml EB buffer. The bisulfite-treated
DNA fragments were PCR amplified: 15ml of eluted DNA, 5 pmol
of Illumina PE PCR primers 1.0 and 2.0, 62.5 nM of each dNTP,
and 2.5 U of Pfu Turbo Cx hotstart DNA polymerase (Stratagene
Products, Agilent, La Jolla, CA) in a total 50ml volume. The
amplification conditions were as follows: 5 min at 95uC, 30 sec at
98uC then 66 (10 sec at 98uC, 30 sec at 65uC, 30 sec at 72uC)
followed by 5 min at 72uC. The PCR reaction was purified by
MinElute PCR purification Kit (Qiagen) and final reduced
representation bisulfite library was eluted in 15ml EB. The
concentration of final library was measured using the Agilent
2100 Bioanalyzer (Palo Alto, CA). The library was sequenced on
Illumina GA sequencing instrument according to standard
Illumina cluster generation and sequencing protocols.
DNA sequencing (50 nt) was conducted on one end of the DNA
fragments. About 62% of all 50 nt sequence tags were uniquely
mapped to the human genome in 3 letter space. A multi-fasta file
of sequences for both forward and reverse strands, consisting of 50
nucleotides or less if the next MspI site is located less than 50
nucleotides apart, adjacent to MspI sites was used as a reference for
alignment. A converted reference, where every C was replaced by
T for forward strand fragments and every G replaced by A for
reverse strand fragments was prepared. All reads from the
Genome Analyzer (qseq files from Bustard) were converted into
three bases (A,G,T), i.e., simply replacing all remaining Cs with Ts.
The converted reads (50 nt) were aligned to converted reference
by stand_alone Eland_extended module. The repeat-masking
option of Eland was used to mask known multiple hits. The
positions from these alignments were used to generate reference
sequences from the original (4 bases) MspI fragments. The original
4 base reads from Genome Analyzer were matched to the
corresponding reference sequences (4 bases). Methylated C base
was obtained by counting C/C+T ratio. Summarized methylation
data on each CpG island were obtained from averaging all CpG
sites with coverage.=10 in a CpG island. These data represent
the percentage of methylated CpGs over total number of CpGs in
the island (from 0 to 100). CpG islands within 5 kb of the 59 end of
a gene were included for the analyses and comparisons. The
overall profile of methylation was examined using unsupervised
hierarchical clustering where distance matrix was 1-Pearson
correlation and the linkage method was average. The differentially
methylated CpG islands were identified using the LIMMA
package, as described for analysis of gene expression. A p-value
cut-off of 0.05 was applied for significantly methylated CpG
islands.
DNA preparation and sequencing
Genomic DNA was extracted using Qiagen’s QIAamp DNA
Mini Kit. Genomic DNA libraries were constructed according to
the standard Illumina protocol. Briefly, DNA (5mg) was fragment-
ed using the Covaris shearing apparatus. The end of digested
DNA was repaired and an adenine was added to the 39 of the
DNA fragments according to the Illumina standard end repair and
add_A protocol. After adaptor ligation using standard Illumina
adaptor ligation protocol, ligated fragments were separated by 2%
agarose gel and DNA fragments of around 400 bp were selected
and purified using Qiagen Gel extraction kit. Size selected DNA
fragments were then amplified using standard Illumina PCR
amplification protocol with 12 PCR cycles. The concentration of
the final library was measured using the Agilent 2100 Bioanalyzer
(Palo Alto, CA). The library was sequenced on Illumina GA
sequencing instrument according to standard Illumina cluster
generation and sequencing protocols. Sequencing was carried out
to a depth of $10 M aligned tags, which corresponds to a
theoretical coverage of about one tag every 300 bp, assuming
3E9bp/genome divided by 1E7 tags/sample.
DNA copy number aberration detection
Genomic 50 bp single end DNA sequencing data were
generated to identify copy number aberrations (CNA) in 7 breast
cancer cell lines in reference to the non-tumor epithelial cell line
(MCF10A). Tumor cell lines were compared to the reference to
obtain log2 ratios using BWA [32] paired-end uniquely mapped
reads to the genome. We identified the CNAs using the
combination of CNV-seq software [33] and Partek Genomics
Suite segmentation algorithm. Specifically, for each sample, we
mapped the filtered BWA alignment reads to a chromosome and
exact base pair locations for input into the CNV-seq software.
CNV-seq software uses a sliding window approach to count
number of mapped reads in a region for each sample and these
counts are used to calculate log2 values. The log2 count values
were normalized at individual chromosome level based on the
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number changes. After normalization we performed median
adjustment to the counts obtained from tumor and reference
samples so that the median log2 values for tumor and reference
were similar. The log2 ratio between a tumor and a reference was
defined by the difference between the median log value of tumor
counts and the median log value of reference counts for a given
segment. To detect copy number changes, we imported the log2
ratio data into Partek Genomic Suite (www.partek.com) and
applied a genomic segmentation algorithm with p-value cutoff at
0.0001 for neighboring regions for significantly different means, 10
minimum number of data points for any candidate region, 0.3
signal to noise difference as minimum magnitude of change, and
p-value threshold 0.0001 for one-sided t-test for a changed region
(below and above thresholds 21 and 0.59, which is equivalent to
log2(1/2)=one copy deletion and log2(3/2)=one copy amplifi-
cation, respectively). We merged the adjacent CNAs and also
obtained overlapped CNAs found in two or more samples using R
package CNTools. Genes that reside in the identified CNA regions
were retrieved using SQL queries according to their genomic
locations. The log2 ratio of that region was used for gene copy
number.
Correlation of mRNA-seq data with methylation and copy
number aberration
Genes in the final analysis were merged with methylation data
and identified copy number aberration regions according to
genomic locations. A scatter plot was created for the genes
that were differentially regulated and for which surrounding
CpG islands were also differentially methylated. A correlation
coefficient between the log2 fold change of gene expression and
mean difference of methylation for these genes was calculated
using Pearson product-moment correlation coefficient, which
ranges from 21 to 1 where 21 and 1 represent perfect negative
and positive correlation and 0 for no correlation. A two-sided
t-test was conducted to compare the correlation coefficient
with 0 and the 95% confident intervals were estimated for
the correlation coefficient. The distance of these CpG islands
from genes was also plotted against the log2 fold change of
differentially expressed gene. In correlating gene expression
with DNA copy number aberrations, average log2 ratio for a
segment from each group (ER+ or ER2) was used to deter-
mine the mean copy number difference between ER+ and
ER2 groups.
Pathway analysis for differentially expressed genes
We conducted pathway analysis for the genes with FDR less
than 0.1 using the genes kept in the final analysis as a reference list
in MetaCore (GeneGo Inc). Both canonical pathways (GeneGo
Maps) and GeneGo process networks were evaluated. In both
analyses, the uploaded focus gene list was compared to the
manually curated and pre-built pathways or biological process
networks using hypergeometric test to get an enrichment p-value
for each pathway or network. The p-value indicates the possibility
of a set of genes that is mapped to a pathway or network by
chance.
Validation of the genes regulated by methylation or
affected by CNA in a public dataset
Our integrated analyses identified a set of 179 genes that were
regulated by methylation (149 genes) or affected by CNA (30
genes) in cell lines. To examine whether these genes were also
differentially regulated in tumor samples, we analyzed a cohort of
129 primary breast cancer gene expression profiles generated
using the Affymetrix U133plus2 platform and downloaded from
Gene Expression Omnibus (GEO accession number: GSE5460)
[8]. The data were log2 transformed and differentially expressed
genes were identified using the t-test. To address the question
whether the set of 179 genes together and the two sets of 149 and
30 genes separately were significantly enriched in this set of
tumor samples, we conducted a gene set enrichment analysis
(GSEA) as described by Subramanian [34]. We evaluated these
user-defined gene sets along with 1,425 well-curated public gene
sets (filtered out 470 gene sets that had fewer than 15 or more
than 500 genes). The phenotypic class was ER+ or ER-status of
the tumors, and the genes that were overexpressed in ER+ or
ER2 tumors were evaluated separately. From this analysis, a
normalized enrichment score (NES), nominal p-value from 1000
permutations, and FDR q-value adjusting for a gene set size and
correlations between gene sets and expression datasets were
obtained.
All the analyses other than specifically noted were conducted in
R: A language and environment for statistical computing (http://
www.r-project.org).
Supporting Information
Table S1 Differential analysis results for mRNA-seq data. It
contains 1,873 genes passing our filtering criteria with log2 fold
change, p value, and false discovery rate q value.
(XLSX)
Table S2 Pathway analysis results for 451 differentially ex-
pressed genes. Only significantly enriched pathways or networks
are listed. Those with bold face have estrogen involvement. P
value was from hypergeometric test. The ratio represents the
number of differentially expressed genes over the total number of
genes in the pathway or network.
(DOCX)
Table S3 Differentially methylated CpG islands and their
associated genes (within 5 kb of transcript start). Both methylation
and gene expression data are included. Note that there are 444
unique CpG islands differentially methylated, with 469 unique
associated genes in the table. Some CpG islands (36) have more
than one gene within 5 kb window. Some genes (10) have more
than one CpG islands within 5 kb of its transcript start.
(XLSX)
Table S4 149 genes (with highlight) whose gene expression was
inversely correlated with CpG island methylation. Both gene
expression and methylation were differentially regulated between
ER+ and ER2 cell lines.
(XLSX)
Table S5 Detected CNA segments in 7 breast cancer cell lines
(reference to MCF10A normal cell line).
(XLSX)
Table S6 Gene expression and CNA data for 30 genes that were
differentially expressed between ER+ and ER2 cell lines and their
copy numbers were consistently changed in ER+ or ER2 cell lines
(amplified in four ER+ cell lines or deleted in three ER2 cell
lines).
(XLSX)
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